Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH Open Label Study of Volanesorsen in FCS
NCT02658175Phase 3Completed
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2015
- Primary completion
- Jan 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 11
01
Overview
Phase 3, open-label trial of volanesorsen in familial chylomicronemia syndrome (FCS) (3 arms), sponsored by Akcea Therapeutics. Primary endpoints: Mean Percent Change From Baseline in Fasting Triglyceride at 12 months and Number of Participants With Treatment-emergent Adverse Events. Started Dec 2015; status: completed.
02
Drugs
volanesorsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT02658175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658175.